CardioSignal is a revolutionary digital cardiac biomarker with the potential to create a paradigm shift in how we diagnose and manage patients with structural heart diseases.

 Heart diseases are the leading global cause of death, and the prevalence of structural heart diseases like heart failure, aortic stenosis, atrial fibrillation, etc. are on the rise. Current diagnostic & monitoring tools for heart diseases are expensive, often invasive and have limited scalability. Missed and late diagnoses can have serious consequences – nearly 40% of patients with heart failure are discovered for the first time after being taken to the emergency room for a heart attack, and >35% of patients suffering a stroke are due to an undetected case of atrial fibrillation.   

 To take a measurement with CardioSignal, the patient places their smartphone in the middle of their chest for a one-minute measurement. CardioSignal’s gyrocardiography technology utilizes motion sensors to monitor angular velocities and rotational motion of the heart. As CardioSignal does not require any additional hardware beyond a smartphone, it has superior scalability and can contribute to more equitable cardiac care.

 CardioSignal’s technology is supported by numerous clinical studies across several structural heart disease indications and 20+ publications in leading clinical journals.